首页> 外国专利> DEVELOPMENT AND CHARACTERIZATION OF PLGA-CHITOSAN-PEG BLENDED POLYMERIC NANOPARTICLES FOR BRAIN TARGETING OF AN ANTIPSYCHOTIC AGENT FOLLOWED BY ORAL ADMINISTRATION.

DEVELOPMENT AND CHARACTERIZATION OF PLGA-CHITOSAN-PEG BLENDED POLYMERIC NANOPARTICLES FOR BRAIN TARGETING OF AN ANTIPSYCHOTIC AGENT FOLLOWED BY ORAL ADMINISTRATION.

机译:PLGA-壳聚糖-PEG共混聚合物纳米微粒的开发和表征,经口服给药后用于脑靶向剂。

摘要

The present investigation was to develop PEGylated poly (lactic-co-glycolic acid) (PLGA) based nanoparticles (PNPs) of Zotepine and to evaluate the brain targeting efficacy following oral administration. Zotepine loaded PNPs were formulated by solvent evaporation technique and were characterized. Stability study was carried out for 3 months. In-vivo study was carried out to ascertain the brain targeting property. Optimal Zotepine loaded PNPs containing ] 00 mg Zotepine, 0.2% w/v of PLGA, 30 mg Chitosan, 25 mg PEG-2000 and 2% PVA was found to be stable with 165.32�3.42 nm, -16.5 �2.86 mV and 73.4+2.71 % as average particle size, zeta potential and % entrapment efficiency (% EE) respectively. TEM result confirmed the size distribution and morphology. PEGytation was confirmed through FT-1R, C13 NMR and 1H NMR study. Comparative in-vitro drug release study showed relatively more sustained release of drug for fabricated formulation than that of marketed formulation. Based on kinetic modeling, the drug release data fit well to Higuchi equation (r2=0.927) indicating the diffusion rate limited drug permeation. Ex-vivo permeation study revealed the rapid permeation which in-tern due to smaller particle size compared to NPs. Higher % DTE of formulation to that of marketed formulation and uncoated PLGA NPs reveal the rapid brain uptake following oral administration which may be due to reduction in the over expression of P-gp mediated efflux mechanism at BBB and its long circulating property. Data of the present study revealed that developed formulation may represent a significant and alternative drug delivery carrier for schizophrenia treatment.
机译:当前的研究是开发Zotepine的基于PEG化聚乳酸-乙醇酸共聚物(PLGA)的纳米颗粒(PNP),并评估口服给药后的脑靶向功效。通过溶剂蒸发技术制备了加载了佐替平的PNP,并对其进行了表征。进行了3个月的稳定性研究。进行了体内研究以确定脑靶向特性。最佳的载有Zotepine的PNP含有00 mg Zotepine,0.2%w / v的PLGA,30 mg壳聚糖,25 mg PEG-2000和2%PVA在165.32.3.42 nm,-16.5.2.86 mV和73.4+下稳定平均粒径分别为2.71%,ζ电位和%包封率(%EE)。 TEM结果证实了其尺寸分布和形态。通过FT-1R,C13 NMR和1H NMR研究证实了PEG化。对比性体外药物释放研究表明,与市售制剂相比,制成制剂的药物相对较缓释。基于动力学模型,药物释放数据非常适合Higuchi方程(r2 = 0.927),表明扩散速率限制了药物的渗透。体外渗透研究表明,与NPs相比,由于较小的粒径,这种渗透很快。相对于市售制剂和未包被的PLGA NPs,更高的DTE%揭示了口服后大脑的快速摄取,这可能是由于BBB上P-gp介导的外排机制的过表达减少及其长期循环特性所致。本研究的数据显示,开发的制剂可能代表精神分裂症治疗的重要且替代性的药物递送载体。

著录项

  • 公开/公告号IN2014MU03659A

    专利类型

  • 公开/公告日2016-05-20

    原文格式PDF

  • 申请/专利权人

    申请/专利号IN3659/MUM/2014

  • 申请日2014-11-19

  • 分类号A61K47/34;A61K48/00;

  • 国家 IN

  • 入库时间 2022-08-21 14:25:19

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号